


IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of
Karl Olmarker

Application No.: 10/506,543

Filing Date: October 13, 2004

Title: NOVEL USE OF CYTOKINE
INHIBITORS

) Group Art Unit: 1653

) Examiner: ROBERT B. MONDESI

) Confirmation No.: 1315

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a SUPPLEMENTAL Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date July 20, 2006

By: Benton S. Duffett Jr.
Benton S. Duffett, Jr.
Registration No. 22030

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Kjell OLMARKER

Application No.: 10/506,543

Filed: October 13, 2004

For: NOVEL USE OF CYTOKINE
INHIBITORS

)
)
)
)
)
)
)
)
)
)
)

Group Art Unit: 1653

Examiner: ROBERT B. MONDESI

Confirmation No.: 1315

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant provides information in conformance with 37 C.F.R. §§ 1.97 or 1.98.

This will supplement the earlier Information Disclosure Statement filed on October 13, 2004.

Applicant provides a copy of a June 23, 2006 Official Action (i.e., Communication Pursuant to Article 96(2) EPC) that was issued in the European counterpart (i.e. No. 03 713 135.6-2402) of the present Application.

Copies of documents D1 to D5 previously were submitted with the Information Disclosure Statement filed on October 13, 2004. Applicant now provides a copy of document D6.

To assist the Examiner, the document D6 is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned once this document is considered.

The further examination and allowance of this application are respectfully requested.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: July 20, 2006

By:



Benton S. Duffett, Jr.
Registration No. 22030


P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application	10/506,543
Filing Date	October 13, 2004
First Named Inventor	Kjell OLMARKER
Examiner Name	Robert B. Mondesi
Attorney Docket No.	1003301-000175

Sheet 1 of


U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Black L.E. "Pharmacology review of infliximab BLA" - 21-05-1998-found at internet address:
	http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.